GCM2 mutation in primary hyperparathyroidism - A Case Report
DOI:
https://doi.org/10.12775/JEHS.2024.71.50880Keywords
Primary Hyperparathyroidism, parathyroid hormone, parathyroidectomy, Endocrine System DiseasesAbstract
Primary hyperparathyroidism is a common endocrine disorder. It is characterised by elevated parathyroid hormone (PTH) level causing hypercalcemia. 90-95% of cases have a spontaneous cause, with the remaining 5-10% having a genetic basis. On routine examination, a 47-year-old patient was found to have hypercalcemia, vitamin D deficiency, normal PTH levels and no hypercalciuria. Despite vitamin supplementation, calcemia remained unchanged. Single photon emission computed tomography (SPECT) examination detected possible adenomas in the lower parathyroids regions, and ultrasound revealed an adenoma of the lower left parathyroid gland and hypertrophy of the lower right parathyroid gland. The atypical clinical presentation - young age, inadequate normal PTH levels and the location of the lesions within the two parathyroid glands suggested genetic testing, which confirmed the presence of a genetic mutation - the GCM2 variant. Treatment included exploration of the parathyroid area using fluorescence. Both lower parathyroid glands were dissected. PTH monitoring showed a decrease in baseline levels of more than 50% after surgery. One month after surgery, PTH and calcium levels remained normal. Primary hyperparathyroidism is usually asymptomatic, detected when laboratory tests are performed for another cause. Symptoms include nephrolithiasis, bone and joint pain, osteoporosis, arrhythmias and fatigue. The typical patient has high PTH levels and hypercalcemia, but not every case will be schematic. High serum calcium levels do not always result in increased PTH levels and an in-depth diagnosis is required. The GCM2 mutation, detected in the patient presented here, may occur in familial isolated hyperparathyroidism. Correct diagnosis and treatment is crucial not only for the patient, as it significantly improves their quality of life, but also for their family members, who may also have a genetic mutation and be unaware of the disorder developing in their body.
References
Guan B, Welch JM, Sapp JC, Ling H, Li Y, Johnston JJ, et al. GCM2 -Activating Mutations in Familial Isolated Hyperparathyroidism. The American Journal of Human Genetics. 2016 Nov;99(5):1034–44.
Carneiro-Pla DM, Romaguera R, Nadji M, Lew JI, Solorzano CC, Irvin GL. Does histopathology predict parathyroid hypersecretion and influence correctly the extent of parathyroidectomy in patients with sporadic primary hyperparathyroidism? Surgery. 2007 Dec;142(6):930–5.
Madkhali T, Alhefdhi A, Chen H, Elfenbein D. Primary hyperparathyroidism. Turk J Surg. 2016 Feb 22;32(1):58–66.
Gopinath P, Mihai R. Hyperparathyroidism. Surgery (Oxford). 2011 Sep;29(9):451–8.
Thakker R V. Genetics of parathyroid tumours. J Intern Med. 2016 Dec 16;280(6):574–83.
Marchiori E, Pelizzo MR, Herten M, Townsend DM, Rubello D, Boschin IM. Specifying the molecular pattern of sporadic parathyroid tumorigenesis—The Y282D variant of the GCM2 gene. Biomedicine & Pharmacotherapy. 2017 Aug;92:843–8.
D’Agruma L, Coco M, Guarnieri V, Battista C, Canaff L, Salcuni AS, et al. Increased Prevalence of the GCM2 Polymorphism, Y282D, in Primary Hyperparathyroidism: Analysis of Three Italian Cohorts. J Clin Endocrinol Metab. 2014 Dec;99(12):E2794–8.
Mannstadt M, Holick E, Zhao W, Jüppner H. Mutational analysis of GCMB, a parathyroid-specific transcription factor, in parathyroid adenoma of primary hyperparathyroidism. Journal of Endocrinology. 2011 Aug;210(2):165–71.
Silverberg SJ, Bilezikian JP. The diagnosis and management of asymptomatic primary hyperparathyroidism. Nat Clin Pract Endocrinol Metab. 2006 Sep;2(9):494–503.
Cordellat IM. Hiperparatiroidismo: ¿primario o secundario? Reumatol Clin. 2012 Sep;8(5):287–91.
Bandeira F, Griz L, Chaves N, Carvalho NC, Borges LM, Lazaretti-Castro M, et al. Diagnosis and management of primary hyperparathyroidism: a scientific statement from the Department of Bone Metabolism, the Brazilian Society for Endocrinology and Metabolism. Arquivos Brasileiros de Endocrinologia & Metabologia. 2013 Aug;57(6):406–24.
Hinnie J. The management of primary hyperparathyroidism. Scott Med J. 2013 Nov 8;58(4):251–3.
Riccardi A, Aspir T, Shen L, Kuo CL, Brown TC, Korah R, et al. Analysis of Activating GCM2 Sequence Variants in Sporadic Parathyroid Adenomas. J Clin Endocrinol Metab. 2019 Jun 1;104(6):1948–52.
El Lakis M, Nockel P, Guan B, Agarwal S, Welch J, F. Simonds W, et al. Familial isolated primary hyperparathyroidism associated with germline GCM2 mutations is more aggressive and has lesser rate of biochemical cure. Surgery. 2018 Jan;163(1):34.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Zuzanna Chmielowiec, Magdalena Pach, Natalia Wierzejska, Agnieszka Fugas, Karolina Smykiewicz, Aneta Michalczewska, Agnieszka Nowak, Alicja Partyka, Mariola Dziedzic, Justyna Dobrzańska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 233
Number of citations: 0